ENDRA Life Sciences Inc. Common Stock (NDRA) is a publicly traded Healthcare sector company. As of May 21, 2026, NDRA trades at $5.55 with a market cap of $6.71M and a P/E ratio of -0.63. NDRA moved +0.00% today. Year to date, NDRA is +22.52%; over the trailing twelve months it is +79.32%. Its 52-week range spans $2.90 to $22.68. Analyst consensus is buy with an average price target of $27.00. Rallies surfaces NDRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
ENDRA Validates Portable TAEUS Liver with 0.90 MRI Correlation and AUROC up to 0.99: ENDRA Life Sciences’ multi-site trial of TAEUS Liver on 64 U.S. and Canadian patients showed a 0.90 correlation with MRI-PDFF, AUROC of 0.95–0.99 and mean error of ~3%, with ICC of 0.89 across operators. The portable device costs under $200 per scan and delivers consistent readings independent of BMI.
| Metric | Value |
|---|---|
| Price | $5.55 |
| Market Cap | $6.71M |
| P/E Ratio | -0.63 |
| EPS | $-8.93 |
| Dividend Yield | 0.00% |
| 52-Week High | $22.68 |
| 52-Week Low | $2.90 |
| Volume | 16 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-7.03M |
| Gross Margin | 0.00% |
1 analysts cover NDRA: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $27.00.